Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography

Biomedical Chromatography

Volumn 20, Issue 12, 2006, Pages 1375-1379

  Wang, Yongsheng ^a   Zhao, Xiaoping ^a   Zhong, Jiao ^a   Chen, Yan ^a   Liu, Xiaoquan ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

High performance liquid chromatography; Metabolite; Pharmacokinetics; Pirfenidone; Plasma

Indexed keywords

BODY FLUIDS; CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITES; RATS;

CALIBRATION CURVES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; MOBILE PHASIS; PERCHLORIC ACIDS; PIRFENIDONE; PLASMA PROTEIN; RAT PLASMA; SIMPLE++; SUPERNATANTS;

PHARMACOKINETICS;

DRUG METABOLITE; PIRFENIDONE; SALICYLIC ACID;

ANALYSIS OF COVARIANCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; RELIABILITY; SINGLE DRUG DOSE;

RATTUS;

EID: 33846257175     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.708     Document Type: Article

References (17)

1. Bruss ML, Margolin SB and Giri SN. Pharmacokinetics of orally administered pirfenidone in male and female beagles. Journal of Veterinary Pharmacology and Therapeutics 2004; 27: 361-367.
2. FDA. Guidance for Industry: Bioanalytical Method Validation. Food and Drug Administration, Center for Drug Evaluation and Research: Washington, DC, 2001.
3. Giri SN, Wang Q, Xie Y, Lango J, Morin D, Margolin SB and Buckpitt AR. Pharmacokinetics; and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharmaceutics and Drug Disposition 2002; 23: 203-211.
4. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB and Becker GJ. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. Journal of Nephrology 2001; 14: 453-460.
5. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB and Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. Journal of Laboratory and Clinical Medicine 1995; 125: 779-785.
6. Iyer SN, Margolin SB, Hyde DM and Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Experimental Lung Research 1998; 24: 119-132.
7. Kaibori M, Yanagida H, Uchida Y, Yokoigawa N, Kwon AH, Okumura T and Kamiyama Y. Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats. Transplantation Proceedings 2004; 36: 1973-1974.
8. Kaneko M, Inoue H, Nakazawa R, Azuma N, Suzuki M, Yamauchi S, Margolin SB, Tsubota K and Saito I. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clinical and Experimental Immunology 1998; 113: 72-76.
9. Kehrer JP and Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicology Letters 1997; 90: 125-132.
10. Liu H, Drew P, Cheng Y and Visner GA. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. Journal of Thoracic and Cardiovascular Surgery 2005; 130: 852-858.
11. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM and Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. British Journal of Pharmacology 2001; 133: 687-694.
12. Nicod LP. Pirfenidone in idiopathic pulmonary fibrosis. Lancet 1999; 354: 268-269.
13. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB and Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney International 1998; 54: 99-109.
14. Tada S, Nakamuta M, Enjoji M, Sugimoto R, Iwamoto H, Kato M, Nakashima Y and Nawata H. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clinical and Experimental Pharmacology and Physiology 2001; 28: 522-527.
15. Taniyama M, Ohbayashi S, Narita M, Nakazawa R, Hasegawa S, Azuma N, Teraoka S, Ota K, Yamauchi S and Margolin SB. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. European Journal of Clinical Pharmacology 1997; 52: 77-78.
16. Tsuchiya H, Kaibori M, Yanagida H, Yokoigawa N, Kwon AH, Okumura T and Kamiyama Y. Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. Journal Hepatology 2004; 40: 94-101.
17. Walker JE and Margolin SB. Pirfenidone for chronic progressive multiple sclerosis. Multiple Sclerosis 2001; 7: 305-312.